DFTX vs ERAS Stock Comparison

ERAS currently leads DFTX in this stock comparison, with AIQ scores of 61 vs 59. The clearest difference is quality, while DFTX has the stronger risk resilience profile.

Market data as of Nov 15, 2026 market close· AIQ score gap 2 points
DFTX
Healthcare
vs
ERAS
Healthcare
DFTX
Definium Therapeutics, Inc.
Price
$32.08
Day move
-2.79%
AIQ Score
59/100
Best edge
Risk Resilience
Sector
Healthcare
ERAS
Erasca, Inc.
Leads
Price
$15.66
Day move
-0.76%
AIQ Score
61/100
Best edge
Quality
Sector
Healthcare

What is the main difference between DFTX and ERAS?

ERAS leads the current stock comparison as Erasca, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Definium Therapeutics, Inc. vs Erasca, Inc.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 59/66 fields· Moderate confidence
AIQ VerdictFragileAIQ Comparison Conviction 2/10

ERAS leads

ERAS leads by 2 AIQ points, primarily on Quality, having only recently taken the lead back from DFTX.

Fragile: 1 of 4 evidence groups support ERAS, the lead recently changed hands, and its current signal state is conflicted.

Evidence agreement: 1 of 4Comparison trend: Reversed
DFTX

Definium Therapeutics, Inc.

AIQ Score
59/100
AIQ Edge Score
10/10
ERAS

Erasca, Inc.

Leads
AIQ Score
61/100
AIQ Edge Score
10/10

The Algovestiq AIQ Score currently favors ERAS over DFTX, 61 versus 59 as of Nov 15, 2026. ERAS's advantage is driven primarily by stronger quality, while DFTX holds the stronger risk resilience profile. ERAS also shows the stronger technical structure relative to its 50-day moving average. 1 of 4 covered evidence groups favor ERAS today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 2 points. ERAS lead: Reversed — DFTX led by 17 AIQ points 30 sessions ago; ERAS now leads by 2.

Compare Definium Therapeutics, Inc. and Erasca, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

DFTX
-4.5%
ERAS
-20.7%

Price return comparison

Growth of $10,000, price only

DFTX $9,548 · ERAS $7,929

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare DFTX and ERAS against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

DFTX advantage
0
ERAS advantage
  • Quality60 vs 65
    ERAS +5
  • Risk Resilience44 vs 39
    DFTX +5
  • Momentum64 vs 67
    Even

1 of 4 evidence groups favor ERAS. ERAS’s edge is concentrated in quality; DFTX keeps a meaningful risk resilience edge.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

DFTX+1 AIQ

No factor moved materially.

New signals

  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
ERAS+9 AIQ

Largest factor move: Quality +21

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • Accumulation Pattern — bullish, volume, medium horizon (1.70x)

The lead changed hands: ERAS moved ahead of DFTX in the latest session.

Deeper signal detail for each name lives on its own signals page — DFTX and ERAS both carry a full feed there.

The central trade-off

ERAS (Erasca, Inc.): the stronger current systematic profile, led by quality.

DFTX (Definium Therapeutics, Inc.): the counter-case, on risk resilience, fundamentals.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

ERAS

ERAS on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

DFTX

DFTX on combined revenue and EPS growth.

Value

Even

The two are level on Value.

Momentum

Even

The two are level on Momentum.

Lower downside

DFTX

DFTX on Risk Resilience, by 5 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasureDFTXERASNote
Implied upside to target+135.3%—Level
Target dispersion+11.9%—Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering199Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

1 of 4 covered evidence groups favor ERAS. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreEven59 vs 61
FundamentalsDFTXrevenue growth 0% vs 0%; EPS growth 74.3% vs -7.1%; TTM ROE -5.3% vs -5.6%; gross margin 0% vs 0%; operating margin 0% vs 0%
ValuationNot coveredNot covered
TechnicalsERASPrice vs 50-day -11.1% vs 4.7%; vs 200-day 5.4% vs 2.6%
Risk ResilienceDFTXRisk Resilience 44 vs 39
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DFTX and ERAS and are excluded from the count.

AIQ Decision Stability

Fragile

The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.

  • The AIQ gap is narrow at 2 points. (argues the conclusion is provisional)
  • Only 1 of 4 covered evidence groups agree. (argues the conclusion is provisional)
  • The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
  • The lead has swung materially session to session. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ERAS.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

ERAS lead: Reversed — DFTX led by 17 AIQ points 30 sessions ago; ERAS now leads by 2.

May 27DFTX leads above the line · ERAS leads belowNov 13
Today
ERAS +2
59 vs 61
7 sessions ago
DFTX +7
58 vs 51
30 sessions ago
DFTX +17
58 vs 41
90 sessions ago
DFTX +13
72 vs 59

The lead changed hands once in this window, most recently on Nov 13 when ERAS moved ahead of DFTX.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

DFTXConflicted

1 bullish / 3 bearish / 1 neutral, conflicted

Only DFTX

  • Golden Cross Active — bullish, trend, long horizon (18.54%)
  • MACD Bearish Crossover — bearish, momentum, short horizon
  • MACD Histogram Expanding Bearish — bearish, momentum, short horizon
ERASConflicted

2 bullish / 2 bearish / 2 neutral, conflicted

Only ERAS

  • Death Cross Active — bearish, trend, long horizon (2.00%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • Accumulation Pattern — bullish, volume, medium horizon (1.70x)
  • EMA Ribbon Expansion Bullish — bullish, trend, medium horizon

Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, Beta Spike Warning.

ERAS leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

DFTXDivergence

Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.79%, AIQ +1 points).

ERASDivergence

Price is down while the AIQ Score moved up 9 points over the same session — price and model disagree (price -0.76%, AIQ +9 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1DFTX closes the Quality gap — currently 5 points behind, the largest single contributor to ERAS's edge.
  2. 2DFTX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3ERAS's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
  4. 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

DFTX leads on balance
MetricDFTXERAS
Revenue growth (YoY)0%0%
EPS growth (YoY)74.3%-7.1%
Gross margin0%0%
Operating margin0%0%
Return on equity (TTM)-5.3%-5.6%
Debt to equity0.040.05

Performance

ERAS leads 6 of 6 windows
MetricDFTXERAS
1 week (5 sessions)-3.6%8.7%
1 month (20 sessions)-0.1%17%
3 months (63 sessions)-29.1%-14.3%
6 months (126 sessions)52.8%53.1%
Year to date139.6%321%
1 year (252 sessions)164.3%490.9%

Technicals

ERAS has the stronger structure
MetricDFTXERAS
RSI (14)41.653.8
ADX (14)1511.6
Price vs 50-day-11.1%4.7%
Price vs 200-day5.4%2.6%
Volatility (1M, annualized)75.9%81.1%

Risk

DFTX is the more resilient
MetricDFTXERAS
Beta1.141.62
Sharpe ratio1.612.29
Sortino ratio3.343.65
Max drawdown-37.3%-59.5%
Current drawdown-33.8%-30.3%
Annualized volatility77.7%102.7%
Value at risk (95%)-5.4%-6.6%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, DFTX or ERAS?

On the Algovestiq AIQ Score, ERAS is the stronger of the two as of Nov 15, 2026, scoring 61 against DFTX's 59. The edge comes from quality. DFTX is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is DFTX or ERAS the better buy right now?

ERAS carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 1 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 2 points. Treat the lead as provisional.

Why does the AIQ Score favor ERAS over DFTX?

The composite weights Quality, Value, Momentum and Risk Resilience. ERAS leads Quality by 5 points; DFTX leads Risk Resilience by 5 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, DFTX or ERAS?

Analyst price targets imply +135.3% upside for DFTX and not covered for ERAS. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, DFTX or ERAS?

Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, DFTX or ERAS?

DFTX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, DFTX or ERAS?

The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, DFTX or ERAS?

DFTX is the more resilient of the two, so the other name carries the higher downside risk. DFTX on Risk Resilience, by 5 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is DFTX more profitable than ERAS?

Margin data is not comparable for both names in the current snapshot.

Is ERAS's lead over DFTX getting stronger or weaker?

ERAS lead: Reversed — DFTX led by 17 AIQ points 30 sessions ago; ERAS now leads by 2. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-11-13, when ERAS moved ahead of DFTX.

What would change the DFTX vs ERAS verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: DFTX closes the Quality gap — currently 5 points behind, the largest single contributor to ERAS's edge; DFTX's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; ERAS's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.

What do the current signals say about DFTX and ERAS?

DFTX: 1 bullish / 3 bearish / 1 neutral, conflicted. ERAS: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DFTX is Golden Cross Active (bullish, long horizon). On ERAS it is Death Cross Active (bearish, long horizon).

Compare DFTX and ERAS with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.